Search Results

You are looking at 81 - 90 of 899 items for :

  • "metastases" x
  • Refine by Access: All x
Clear All
Full access

Role of Lymph Node Dissection in Primary Surgery for Thyroid Cancer

Elizabeth G. Grubbs and Douglas B. Evans

cervical lymph node metastases from papillary carcinoma of the thyroid . Br J Surg 2001 ; 88 : 1241 – 1244 . 21. Machens A Hinze R Thomusch O Dralle H . Pattern of nodal metastasis for primary and reoperative thyroid cancer . World J Surg

Full access

Risk Factors for Development of Hypocalcemia in Patients With Cancer Treated With Bone-Modifying Agents

Paul S. White, Michael Dennis, Eric A. Jones, Janice M. Weinberg, and Shayna Sarosiek

subcutaneously administered monoclonal antibody. They are indicated in the treatment and prevention of bone metastases and skeletal-related events and of osteoporosis in patients receiving hormone therapy. 1 – 6 These agents are also routinely used for

Full access

Principles of Surgical Management of Peritoneal Mesothelioma

Jessica A. Steadman and Travis E. Grotz

definitive PCI determined at laparotomy. 34 Stage I refers to patients with a PCI ≤10 (T1), stage II includes patients with PCI 11–20 (T2) and 21–30 (T3), and stage III includes patients with PCI 30–39 (T4), any nodal disease (N1), or any distant metastases

Full access

Optimize Local Therapy for Oligometastatic and Oligoprogressive Non–Small Cell Lung Cancer to Enhance Survival

Joe Y. Chang and Vivek Verma

not. 3 , 5 In addition, brain metastases have historically been associated with a poorer prognosis and have been highly underrepresented in existing randomized trials ( Table 1 ); whether these patients receive the same benefit from local therapy as

Full access

Targeted Therapy for Patients With Metastatic Non–Small Cell Lung Cancer

Karen L. Reckamp

in patients with and without brain metastases, and has less toxicity than either the first- or second-generation EGFR TKIs. Virtually all patients who experience response to frontline EGFR TKI therapy develop resistance. The most common mechanism of

Full access

Current Concepts in Penile Cancer

Philippe E. Spiess, Simon Horenblas, Lance C. Pagliaro, Matthew C. Biagioli, Juanita Crook, Peter E. Clark, Richard E. Greenberg, and Cesar E. Ercole

adopting a multimodal approach consisting of neoadjuvant systemic chemotherapy followed by consolidative surgical resection in patients presenting with bulky/locally advanced nodal metastases from penile cancer. In 2013, an estimated 1570 new cases of

Full access

Management of Patients With Aggressive Nonmelanoma Skin Cancers

Presented by: Valencia D. Thomas, Michael K. Wong, and Andrew J. Bishop

, provide an outline for patient stratification based on risk factors for local recurrence, metastases, and death from disease ( Figure 1 ). 2 “There are so many characteristics and elements that we must take into consideration that there are conflicting

Full access

Point: Sentinel Lymph Node Biopsy Is Indicated for Patients With DCIS

Hiram S. Cody III and Kimberly J. Van Zee

; 233 : 537 – 541 . 39 Fourquet A de la Rochfordiere A Campana F . Occult primary breast cancer with axillary metastases . In Harris JR , Lippman ME , Morrow M , Hellman S (eds). Diseases of the Breast. Philadelphia : Lippincott

Full access

HSR19-078: Human Papillomavirus Status and Survival Among Patients With Oropharyngeal Cancer: Analyses of a United States Health System

Himani Aggarwal, Li Li, Gebra Cuyun Carter, Kathy Fraeman, and Ariel Berger

.5%; P =.01), or distant metastases (1.8% vs 9.5%; P =.029) vs HPV-negative patients. Among HPV-positive patients, 75.5%, 12.7%, and 10.9% had squamous cell carcinoma NOS, basaloid squamous cell carcinoma, and squamous cell carcinoma large cell non

Full access

Melanoma, Version 2.2013

Featured Updates to the NCCN Guidelines

Daniel G. Coit, Robert Andtbacka, Christopher J. Anker, Christopher K. Bichakjian, William E. Carson III, Adil Daud, Dominick DiMaio, Martin D. Fleming, Valerie Guild, Allan C. Halpern, F. Stephen Hodi Jr., Mark C. Kelley, Nikhil I. Khushalani, Ragini R. Kudchadkar, Julie R. Lange, Anne Lind, Mary C. Martini, Anthony J. Olszanski, Scott K. Pruitt, Merrick I. Ross, Susan M. Swetter, Kenneth K. Tanabe, John A. Thompson, Vijay Trisal, Marshall M. Urist, Nicole McMillian, and Maria Ho

metastases who would be at higher risk of recurrence and who might be candidates for complete lymph node dissection or adjuvant systemic therapy. A large meta-analysis, including 71 studies and 25,240 participants, estimated the risk of nodal recurrence after